Palisade Bio Inc

Palisade Bio Inc a clinicalstage biopharmaceutical company focuses on discovering developing and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract Its lead therapeutic candidate is LB1148 an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine infections or due to surgery The company was founded in 2005 and is headquartered in Carlsbad California